Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 1st Qtr Business Results
September 6, 2004
- Unfair Contracts Still Noted between Wholesalers and Med Institutions: Survey
September 6, 2004
- NEW PRODUCTS
September 6, 2004
- Thinking CRAs Needed: Quintiles Seminar
September 6, 2004
- Daiichi to Strengthen Marketing of Omnipaque in Outpatient Care
September 6, 2004
- BUSINESS NEWS IN BRIEF
September 6, 2004
- Norvasc Was Japan's Top-selling Drug in April-June: IMS Japan
September 6, 2004
- Amended GMP GL at the Final Stage of Preparation
September 6, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
September 6, 2004
- Korosho's FY2005 Draft Budget Request Reaches \21.26 Trillion
September 6, 2004
- MEDICAL DEVICE NEWS IN BRIEF
September 6, 2004
- METI's FY2005 Draft Budget Request Seeks 14.8% Increase
September 6, 2004
- NEW PRODCUTS
September 6, 2004
- Medical Costs Up 2.1% to \30.8 Trillion in FY2003
September 6, 2004
- DIAGNOSTIC NEWS IN BRIEF
September 6, 2004
- National Medical Costs in FY2002 Decline 0.6% to \31 Trillion
September 6, 2004
- OTC NEWS IN BRIEF
September 6, 2004
- Korosho to Steadily Implement Its Industry Visions: Mr Futagawa
September 6, 2004
- WORLD NEWS IN BRIEF
September 6, 2004
- Korosho to Work to Increase Speed, Reliability of NDA Review: Mr Kawahara
September 6, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…